The C.A.M. Report
Complementary and Alternative Medicine: Fair, Balanced, and to the Point
  • About this web log

    This blog ran from 2006 to 2016 and was intended as an objective and dispassionate source of information on the latest CAM research. Since my background is in pharmacy and allopathic medicine, I view all CAM as advancing through the development pipeline to eventually become integrated into mainstream medical practice. Some will succeed while others fail. But all are treated fairly here.

  • About the author

    John Russo, Jr., PharmD, is president of The MedCom Resource, Inc. Previously, he was senior vice president of medical communications at, a complementary and alternative medicine website.

  • Common sense considerations

    The material on this weblog is for informational purposes. It is not medical advice or counsel. Be smart, consult your health professional before using CAM.

  • Recent Posts

  • Recent Comments

    A pharmacogenomic-CAM connection in diabetes

    Dr. Andrew Levy from Technion-Israel Institute of Technology in Haifa makes the case for a new pharmacogenomic blood test that can be used to identify diabetes patients at highest risk for cardiovascular disease.

    Presently, medical costs of treating cardiovascular complications of diabetes are more than $100 billion per year in the US.

    Dr. Levy and colleagues have discovered a new risk factor — the haptoglobin (Hp) 2-2 gene — that identifies people with diabetes who are up to 5 times more likely to develop cardiovascular disease. The problem is that Hp 2-2 diabetic patients experience greater oxidative stress. By comparison, patients with the Hp 1-1 gene are better able to minimize oxidative stress.

    The Hp gene type has no impact on cardiovascular risk in people without diabetes.

    The CAM connection.
    Of potential greater importance are the results of 2 studies this year where giving vitamin E to Hp 2-2 diabetic patients resulted in greater protection from heart attack, stroke, and death due to cardiovascular causes.

    These results are at odds with earlier vitamin E studies, which reported neutral or negative effects in diabetics. However, reanalysis of one or these studies indicates that the Hp 2-2 diabetic patients benefited from vitamin E even if the entire population of study patients did not.

    Best of all, Dr. Levy concludes, the Hp 2-2 test only needs to be preformed once following diagnosis of type 1 or type 2 diabetes.

    The potential public health and economic benefits from this pharmacogenomic test in patents with diabetes are enormous.

    The test should be available later this year.

    9/4/08 19:16 JR

    Leave a Comment

    You must be logged in to post a comment.